Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CBMG Says Bi-Specific CAR-T Effective in Non-Hodgkin Lymphoma Trial

publication date: Jun 11, 2021

CBMG Holdings, a US-China immunotherapy company, said its novel bi-specific CAR-T candidate was effective in an early-stage China lymphoma trial. C-CAR039, a second-gen 4-1BB CD19/CD20 bi-specific, produced an overall 92% overall response rate in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). The complete response rate was 85%. In addition, the US FDA granted orphan drug designation to C-CAR039 in patients with follicular lymphoma. CBMG was known as Cellular Biomedicine before it was taken private in a management-led buyout. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here